Endothelium-Derived Hyperpolarizing Factor and Vascular Function

Muhiddin A. Ozkor, University College London
Arshed Ali Quyyumi, Emory University

Journal Title: Cardiology Research and Practice
Volume: Volume 2011, Number 2011
Publisher: Hindawi Publishing Corporation | 2011-05-27, Pages 1-12
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.4061/2011/156146
Permanent URL: http://pid.emory.edu/ark:/25593/f77w7

Final published version: http://www.hindawi.com/journals/crp/2011/156146/

Copyright information:
© 2011 Muhiddin A. Ozkor and Arshed A. Quyyumi.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed August 22, 2023 4:20 AM EDT
Review Article

Endothelium-Derived Hyperpolarizing Factor and Vascular Function

Muhiddin A. Ozkor1 and Arshed A. Quyyumi2

1 The Heart Hospital, University College London, London WIG 8PH, UK
2 Division of Cardiology, Department of Medicine, Emory University, 1364 Clifton Road NE, Suite 403C, Atlanta, GA 30322, USA

Correspondence should be addressed to Arshed A. Quyyumi, aquyyum@emory.edu

Received 7 March 2011; Revised 27 May 2011; Accepted 27 May 2011

Academic Editor: Abarmand Maziar Zafari

Copyright © 2011 M. A. Ozkor and A. A. Quyyumi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Endothelial function refers to a multitude of physiological processes that maintain healthy homeostasis of the vascular wall. Exposure of the endothelium to cardiac risk factors results in endothelial dysfunction and is associated with an alteration in the balance of vasoactive substances produced by endothelial cells. These include a reduction in nitric oxide (NO), an increase in generation of potential vasoconstrictor substances and a potential compensatory increase in other mediators of vasodilation. The latter has been surmised from data demonstrating persistent endothelium-dependent vasodilatation despite complete inhibition of NO and prostaglandins. This remaining non-NO, non-prostaglandin mediated endothelium-dependent vasodilator response has been attributed to endothelium-derived hyperpolarizing factor/s (EDHF). Endothelial hyperpolarization is likely due to several factors that appear to be site and species specific. Experimental studies suggest that the contribution of the EDHFs increase as the vessel size decreases, with a predominance of EDHF activity in the resistance vessels, and a compensatory up-regulation of hyperpolarization in states characterized by reduced NO availability. Since endothelial dysfunction is a precursor for atherosclerosis development and its magnitude is a reflection of future risk, then the mechanisms underlying endothelial dysfunction need to be fully understood, so that adequate therapeutic interventions can be designed.

1. Introduction

Endothelial function refers to a multitude of physiological processes of the vascular endothelium that maintain healthy homeostasis of the vascular wall and may be used as a “barometer” of the injury/repair inflicted by multiple environmental and genetic factors [1–3]. Vascular endothelial dysfunction is associated with a reduction in nitric oxide (NO) bioavailability, an increase in generation of potential vasoconstrictor substances such as superoxide anions and endothelin–1, and a potential compensatory increase in other mediators of vasodilation. This remaining non-NO, non-prostaglandin-mediated endothelium-dependent vasodilation has been partly attributed to endothelium-derived hyperpolarizing factor/s (EDHF). Endothelial hyperpolarization is likely due to several factors that are site- and species-specific, ultimately causing vascular smooth muscle hyperpolarization and relaxation. Experimental studies suggest that the contribution of EDHFs increase as the vessel size decreases, with predominant EDHF activity in the resistance vessels and a compensatory upregulation of EDHFs in states characterized by reduced NO availability [4–12]. Whereas prostacyclin and NO bioavailability have been extensively investigated in the human circulation in vivo, little is known about endothelial hyperpolarization.

2. Endothelium-Derived Hyperpolarizing Factor (EDHF)

Potential EDHFs differ by species and vascular bed, but act by increasing potassium (K+) conductance resulting in the subsequent propagation of depolarization of vascular smooth muscle cells and relaxation [13–15] (Figure 1). Acetylcholine causes hyperpolarization of vascular smooth muscle in arteries with an intact endothelium but not in its absence [16–19]. This hyperpolarization is mimicked by
**Figure 1**: Mechanisms for endothelial cell mediated relaxation. Agonist (bradykinin/acetylcholine/substance P) or shear stress increases the activity of endothelial NO synthase (eNOS) and cyclooxygenase (COX), providing nitric oxide (NO) and prostacyclin (PGI²)-mediated dilation. There are multiple potential EDHF pathways. Increases in intracellular calcium activates phospholipase A2 (PLC) to produce arachidonic acid. Its metabolism by cytochrome P450 2C (CYP450 2C) generates eicosatrienoic acids (EETs) that can stimulate calcium dependent potassium (KCa+) channels in endothelial and smooth muscle cells. EETs may also directly activate gap junctions (Gap). EETs may also act in an autocrine manner on endothelial cells by activating transient receptor potential (TRP) V4 channels, which promote Calcium (Ca++) influx further increasing the calcium concentration and activating KCa+ channels to cause hyperpolarization and release of K+ ions into the subendothelial space. The increase in potassium in the interstitium may activate KIR+ channels, inwardly rectifying potassium channels (KIR+), or the Na+-K+ pump on smooth muscle cells and cause hyperpolarization. Smooth muscle hyperpolarization in turn results in relaxation by closing voltage-gated channels leading to a fall in Ca++ concentration and subsequent vasodilation. The action of eNOS (with cofactor tetrahydrobiopterin [BH4]) and oxidases on oxygen (O2) produces the reactive oxygen species superoxide (O2−). Hydrogen peroxide (H2O2) generated by dismutation of superoxide anions by superoxide dismutase (SOD) can also cause hyperpolarization by activating endothelial and smooth muscle KCa+ channels or by gap junctions. Adenylyl cyclase: AC; cyclic Adenosine monophosphate: cAMP; cyclic guanosine monophosphate: cGMP; soluble guanylyl cyclase: sGC; prostacyclin receptor, IP.

---

certain K+ channel agonists and is unaffected by inhibitors of nitric oxide synthase or cyclooxygenase and has been attributed to release of EDHF/s. EDHFs appear to open smooth muscle cell K+ channels, allowing K+ efflux along its chemical gradient resulting in membrane hyperpolarization. Thus, EDHF activity may be defined functionally as agonist-induced, endothelium-dependent relaxation that is not blocked by inhibitors of NO synthase or cyclooxygenase but can be inhibited, at least in part, by K+ channel blockers.

### 2.1. Potassium (KCa+): Channel Activation (Figure 1)

**2.1.1. Calcium-Activated Potassium (KCa+) Channels.** Agonists such as bradykinin stimulate endothelial G protein-coupled receptors provoking an increase in intracellular calcium [Ca2+], in the endothelial cell [20, 21]. Endothelium-dependent hyperpolarization of smooth muscle cells results from the opening of K+ channels in the smooth muscle plasmalemma and is abolished by K+ concentrations higher than 25 mM [22]. Agonists that produce hyperpolarization also stimulate efflux of K+ [17, 23]. However, there are several smooth muscle K+ channels; endothelium-dependent hyperpolarization is not prevented by glibenclamide, an inhibitor of ATP-dependent K+ channels (KATP), or inhibitors of inwardly rectifying potassium channels (KIR+) [24]. However, both barium chloride (<100 μmol/L) and ouabain (2.7 nmol/min), inhibitors of KIR+ channels, reduced resting flow in healthy subjects, an effect that was lower in obesity, even though these are not endothelium-dependent responses [25].

The hallmark of the EDHF-mediated responses is its abolition by the combination of apamin (a specific inhibitor of KCa+ channels of small conductance (SKCa+ channels)) plus charybdotoxin (a nonselective inhibitor of large-conductance (BKCa+) and intermediate-conductance (IKCa+) channels), and of some voltage-dependent K+ (KV+ channels) [26–28]. This toxin combination targets KCa+ channels on endothelial cells rather than K+ channels located on smooth
muscle cells. Increasing intracellular free calcium in endothelial cells opens $\mathrm{K}_{\text{Ca}}^+$ channels allowing efflux and accumulation of $\mathrm{K}^+$ into the myoendothelial space. This triggers several processes that explain the EDHF phenomena; including (1) synthesis of cytochrome that P450 (CYP450) metabolites, a family of epoxides, (2) transmission of endothelial cell hyperpolarization to the vascular smooth muscle via gap junctions, and (3) $\mathrm{K}^+$ released from the endothelial cells via $\mathrm{K}_{\text{Ca}}^+$ channels induces smooth muscle hyperpolarization by activating $\mathrm{K}_{\text{Ca}}^+$ channels and/or $\mathrm{Na}^-\mathrm{K}^+$-ATPase on vascular smooth muscle cells.

Study of gastroepiploic conductance arteries and microvessels revealed that the contribution of EDHF to endothelium-dependent relaxations is significantly larger in human microvessels than in large arteries, that EDHF-mediated relaxations are mediated via activation of $\mathrm{K}^+$ channels, and that risk factors, particularly hypercholesterolemia and aging, were associated with impaired EDHF-mediated dilatation [4]. Convincing evidence has been presented to suggest that a CYP450-dependent EDHF plays a significant role in the regulation of coronary arteriolar tone by $\mathrm{K}_{\text{Ca}}^+$ channel activation and smooth muscle hyperpolarization [8, 29]. Thus, L-NG-nitro arginine/indomethacin-insensitive component of acetylcholine-mediated relaxation was sensitive to 25 mmol/L $\mathrm{K}^+$, but not to glibenclamide, a $\mathrm{K}_{\text{ATP}}$ channel inhibitor. Importantly, relaxation in human subcutaneous resistance arteries was abolished by a combination of charybdotoxin and apamin indicating the crucial role for endothelial $\mathrm{K}_{\text{Ca}}^+$ channel activation [7].

Human studies have used tetraethylammonium chloride (TEA) to investigate the role of large $\mathrm{K}_{\text{Ca}}^+$ channel activation on forearm blood flow and on the vascular effects of bradykinin. TEA selectively blocks $\mathrm{K}_{\text{Ca}}^+$ channels in arterial smooth muscle cells at concentrations of >1 mmol/L [29]. At these doses, TEA decreased resting forearm blood flow by 23% and radial artery diameter by 5%, and it also inhibits bradykinin-and substance P-induced, but not acetylcholine-mediated vasodilation after inhibition of NO and prostaglandins in the forearm microcirculation [30–32]. Moreover, resting radial arterial blood flow and diameter were reduced only with combined blockade of NO synthesis and $\mathrm{K}_{\text{Ca}}^+$ channels but not with either blockade individually, suggesting an important interaction between these two vasodilator systems [31]. These observations demonstrate the contribution of both NO and $\mathrm{K}_{\text{Ca}}^+$ channel activation to resting conductance artery and microvascular tone in the healthy human forearm circulation.

2.2. Epoxyeicosatrienoic Acids (EETS) (Figure 1). Epoxyeicosatrienoic acids (EETS) are arachidonic acid derived products of cytochrome P450 (CYP450) epoxygenases [33]. CYP450 enzymes are membrane-bound, heme-containing terminal oxidases in a multi-enzyme system. The arachidonic acid metabolizing CYP450 enzymes with prominent roles in vascular regulation are the epoxygenases of the CYP 2 gene family (e.g., CYP 2B, 2C8, 2C9, 2C10, and 2J2 in humans) that generate a series of region-specific and stereo-specific epoxides (5,6-, 8,9-, 11,12-, and 14,15-EETs), and the arachidonic acid v-hydroxylases belonging to the CYP 4A family which form hydroxyeicosatetraenoic acids (HETEs) which can demonstrate organ specific opposed actions [34].

Evidence in favor of EDHF being a short-lived metabolite of the cytochrome P450 epoxygenase pathway has been obtained using bovine [35, 36], porcine [36, 37], canine [38, 39], murine [40, 41], and human coronary arteries [8, 9, 29, 42–45]. EDHF-mediated responses are blocked by nonspecific CYP450 inhibitors such as miconazole, 17-octadecynoic acid, and more selective epoxide inhibitors [6–2-(propargyl oxyphenyl) hexanoic acid and N-methyl-sulphonyl-6-(2-proparglyoxyphenyl) hexanamide] [46–48]. RT-PCR, Western blotting, and immunofluorescence techniques have demonstrated that native coronary endothelial cells express CYP epoxygenases, including CYP 2C8, CYP 2C9, and CYP 2J2 [49–52]. EET-induced activation of $\mathrm{K}_{\text{Ca}}^+$ channels appears to be mediated by a cascade of intracellular events involving the ADP ribosylation of cellular proteins including anti-G(S)alpha antibody [53, 54] ultimately hyperpolarizing smooth muscle cells by increasing the open-state probability of $\mathrm{K}_{\text{Ca}}^+$ channels [35, 41, 50, 55]. In porcine coronary arteries, a CYP450-derived epoxide, namely 11,12-epoxyeicosatrienoic acid (11,12-EET) has been shown to possess EDHF properties because (1) both 11,12-EET and bradykinin elicit hyperpolarization; (2) endothelial cells, but not smooth muscle cells, expressed mRNA and protein for the epoxygenase enzyme of the CYP2C family and released 11,12-EET; (3) induction of CYP2C8 or CYP2C34 increased epoxyeicosatrienoic expression, which was associated with increased release of 11,12-EET, and enhanced relaxation and hyperpolarization in response to bradykinin; (4) an antisense oligonucleotide directed at the endothelial epoxygenase reduced both CYP2C mRNA and protein expression and the capacity to generate 11,12-EET, concomitantly with a reduction in the vasorelaxant and hyperpolarizing response to bradykinin [50]. The finding that sulfaphenazole, a selective inhibitor of CYP 2C9 [56, 57], inhibits EDHF-mediated responses [50] and potentiates non-NO-mediated relaxation in the porcine coronary artery [33] suggests that the CYP isozyme required for the generation of EDHF is a porcine equivalent of CYP 2C9 [58]. Further, there is evidence in some species that CYP450-derived epoxides stimulate Na+/K+ ATPase [59]. These data strongly suggest that the activation of a cytochrome P450 epoxygenase is a prerequisite for the generation of EDHF-mediated relaxation in certain species.

Other intracellular second messenger roles of EETs may be equally as important in the control of vascular homeostasis. EETs (in particular 11,12- and 14,15-EET) activate several intracellular protein kinases including tyrosine kinases, the p38 MAP kinase, and extracellular-regulated protein kinases 1 and 2 (Erk1/2) and increase the proliferation of various cell types, including vascular smooth muscle cells and endothelial cells [33, 60, 61].

In isolated human coronary arterioles, CYP450-dependent hyperpolarization plays a significant role in the regulation of smooth muscle tone via activation of $\mathrm{K}_{\text{Ca}}^+$ channels [8, 29]. Human coronary arteriolar endothelium-dependent hyperpolarization in response to arachidonic acid is much more dependent on metabolism by CYP450 than by
vasodilator tone. In the largest cohort studied to date, an
controversies regarding the contribution of EDHF to resting
EETs on maintenance of basal tone when NO availability is
becomes evident after inhibition of NO and prostacyclin
by tonic activity of CYP450-derived epoxides, their role
conductance and resistance vessel tone is not modulated
flow [31, 63, 64], but after inhibition of NO and prostacyclin,
does not alter conductance vessel diameter or resting blood
31, 63].

forearm
in vivo
channels, to resting microvascular dilator tone in the human
endothelium and smooth muscle cells. Thus, in human in-
ternal mammary arteries, EDHF appears to be 11,12-EET,
produced by an EDHF synthase CYP450-2C and accounts
for 40% of net endothelial relaxation by stimulating large-
conductance KCa+ channels [6].

The role of EETs as potential EDHFs can be studied
using azoles such as miconazole that selectively inhibit
epoxidation (EET generation) of arachidonic acid and have
been demonstrated to be partly responsible for endothelium-
dependent vasodilation in the human microcirculation [9,
31, 63]. In vivo studies have demonstrated CYP450 inhibition
does not alter conductance vessel diameter or resting blood
flow [31, 63, 64], but after inhibition of NO and prostacyclin,
inhibition of EET synthesis further decreases radial arterial
blood flow and diameter [31]. Thus, although it appears
that under resting conditions in the healthy human forearm,
conductance and resistance vessel tone is not modulated
by tonic activity of CYP450-derived epoxides, their role
becomes evident after inhibition of NO and prostacyclin
synthesis, illustrating the potential compensatory role of
EETs on maintenance of basal tone when NO availability is
diminished.

In recent studies, we have addressed previous con-
troversies regarding the contribution of EDHF to resting
vasodilator tone. In the largest cohort studied to date, an
important contribution of EDHF, via activation of KCa+ channels,
to resting microvascular dilator tone in the human
forearm in vivo has been demonstrated [65]. For the first
time, we have also demonstrated that cytochrome P450-
derived epoxyeicosatrienoic acids also contribute to resting
vasodilator tone in the healthy microcirculation with the use
of fluniconazole to block their action. We found a relatively
greater contribution of NO compared to EDHF in the main-
tenance of resting vasodilator tone in the healthy human
forearm microvasculature. The contribution of these two
endogenous vasodilators to resting tone differed in subjects
exposed to risk factors for atherosclerosis, in whom the
vasculature is characterized by decreased NO bioavailability.
We found preserved contribution of EDHF that appears to
contribute equally as much as NO to resting vasodilator
tone in subjects with risk factors. In the presence of NO
blockade with L-NMMA, epoxyeicosatrienoic acid-mediated
microvascular vasodilation also appeared to be upregulated
in healthy subjects [65]. This indicates potential cross-talk
between the NO and EET pathways, such that EET activity
is upregulated in the setting of NO deficiency which may
be demonstrated by blocking NO synthesis in the healthy
circulation. Interestingly, in the risk factor group, there
was a similar contribution of EETs to resting tone in the
presence and absence of NO blockade. Such compensation
may be crucial in maintaining normal resting blood flow in
nonhypertensive patients with risk factors.

Finally, by conducting experiments using single and
combined blockade, we also demonstrated that KCa+ channel
activation contributes to microvascular dilator tone even
after inhibition of epoxyeicosatrienoic acids. This indicates
that sources other than epoxyeicosatrienoic acids contribute
to hyperpolarization of the resting human forearm micro-
circulation. Potential candidates which have been investi-
gated in experimental studies, include hydrogen peroxide,
potassium ions, and gap junctions. These alternate pathways
warrant further investigation in vivo in humans.

2.3. Hydrogen Peroxide. Hydrogen peroxide also activates
calcium-dependent potassium channels and remains a con-
tender as an EDHF [66] (Figure 1). Reactive oxygen species
can increase K+ channel activity and hyperpolarize smooth
muscle [67, 68], and hydrogen peroxide may function
as an EDHF [69]. Rubanyi and Vanhoutte reported that
superoxide attenuates endothelium-dependent relaxations
and that hydrogen peroxide causes endothelium-dependent
and -independent relaxations [70]. Matoba et al. utilized
catalase, an endogenous peroxidase to show inhibition of
EDHF-mediated, endothelium-dependent relaxations and
hyperpolarizations, resistant to indomethacin or N(omega)-
nitro-l-arginine [71]. These findings have been confirmed
in piglet pial arteries, canine subepicardial coronary arteries
and arterioles, and during flow-induced vasodilation in
human mesenteric arteries and coronary microvessels [66,
72–74].

Vascular endothelial cells have a capacity to produce su-
peroxide and hydrogen peroxide from several intracellu-
lar sources, including endothelial NO synthase, cyclooxy-
genases, lipooxygenases, cytochrome P-450 epoxygenases,
NAD(P)H oxidases, and xanthine oxidase [71, 75–78]. Flow-
mediated dilation involves generation of superoxide originat-
ing from mitochondria and shear stress elicits luminal release
of mitochondrial ubisemiquinone, a source for generating
superoxide and hydrogen peroxide via metabolic processes
occurring between complex I and complex III of the electron
transport chain [79]. Although reactive oxygen species ap-
pear to fit the profile of EDHF, their physiologic role remains
a subject of debate particularly in some human arteries
because in human radial and internal mammary arteries, nei-
ther catalase nor superoxide dismutase inhibited relaxations
to carbachol [80, 81].

Hydrogen peroxide also mediates hyperpolarization via
activation of endothelial K+ channels, however, many species
variations exist in the type of K+ channels that are activated
[67, 68, 72, 73, 82–84]. Importantly, in human coronary
microvessels, KCa+ channels sensitive to charybdotoxin plus
apamin appear to mediate hyperpolarization [73, 85]. In
mouse mesenteric arteries, the inhibitory effect of catalase
was unmasked by the inhibition of NO production, and vice
versa, suggesting that NO and EDHF (hydrogen peroxide)
compensate for each other [71, 86–89]. In canine subepi-
cardial coronary arteries and arterioles, the response to
cyclooxygenase or lipooxygenase or activation of NO synthase
[8, 62]. The predominant EET synthesized by arteries is
11,12-EET, and its specific inhibition by chemically distin-
tinct CYP450 inhibitors impairs EDHF relaxation. 11,12-
EET activates large-conductance KCa+ channel current and
hyperpolarizes arterial smooth muscle. Large-conductance
KCa+ channels and CYP450-2C mRNA and proteins are less
abundant in arteries than saphenous veins explaining the
lack of EDHF activity of veins. Large-conductance KCa+
channels are primarily present in vascular smooth muscle,
whereas the CYP450-2C enzyme is present in both the
endothelium and smooth muscle cells. Thus, in human in-
ternal mammary arteries, EDHF appears to be 11,12-EET,
produced by an EDHF synthase CYP450-2C and accounts
for 40% of net endothelial relaxation by stimulating large-
conductance KCa+ channels [6].

endothelium and smooth muscle cells. Thus, in human in-
ternal mammary arteries, EDHF appears to be 11,12-EET,
produced by an EDHF synthase CYP450-2C and accounts
for 40% of net endothelial relaxation by stimulating large-
conductance KCa+ channels [6].
acetylcholine and hypoxia was inhibited by L-NMMA primarily in subepicardial coronary arteries, whereas combined infusion of L-NMMA plus catalase or tetraethylammonium attenuated the vasodilator responses of coronary arteries of both sizes, demonstrating the predominance of hydrogen peroxide-mediated hyperpolarization in microvessels [74].

2.4. Gap Junctions. The EDHF phenomenon may be further explained by the transmission of endothelial cell hyperpolarization to the vascular smooth muscle via gap junctions [90–92]. These are myoendothelial and heterocellular. They couple endothelial cells to other endothelial cells and to smooth muscle cells, providing a low-resistance electrical pathway between the cell layers. Gap junctions are formed by the docking of two connexons present in adjacent cells that creates an aqueous pore permitting the transfer of ions and electrical continuity that establishes a uniform membrane potential across cells [93, 94]. Their number increases with diminution in the size of the artery [95], paralleling the importance of EDHF to vessel size with a greater influence in the resistance than in the conductance vessels [96].

Investigation of gap junctions as other potential EDHF mechanisms has been limited in man due to the lack of specific pharmacological agents. Rotigaptide, that enhances communication via the connexin 43 gap junction subunit, had no effect on basal vascular tone endothelium-dependent 

2.5. Potassium (K⁺). A moderate increase in the myoendothelial K⁺ concentration can in some species [98] induce hyperpolarization of vascular smooth muscle cells by activating the inwardly rectifying K⁺ channels and the Na⁺/K⁺ ATPase [24, 99, 100]. However, it is unlikely that K⁺ per se is EDHF.

3. Interactions between EDHF, Nitric Oxide, and Prostacyclin

The three main mediators of endothelial vasodilator function, NO, prostacyclin, and EDHF appear not to be mutually exclusive and act synergistically in a complex manner to maintain the health of the vasculature (Figure 1). In conduit arteries, NO is the predominant endothelium-derived vasodilator but has relatively less prominent contribution in the resistance vessels of the microcirculation where EDHF appears to predominate [96]. NO may tonically inhibit EDHF responses as some studies could only demonstrate EDHF responses once NO production had been inhibited [44].

4. EDHF and Disease

Experimental evidence indicates that a shift away from NO-mediated endothelium-dependent relaxation toward EDHF-dependent relaxation occurs in disease states [101, 102]. Alteration of EDHF-mediated responses has been reported with aging, hypertension, atherosclerosis, hypercholesterolemia, heart failure, angioplasty, eclampsia, diabetes, and sepsis. Depending on the vascular bed, this may either contribute to endothelial dysfunction or compensate for the loss of NO bioavailability [103–105]. In the human forearm of hypertensive subjects, Taddei and others demonstrated that endothelium-dependent vasodilation is maintained despite decreased NO bioavailability because of the compensatory increased activity of EDHF [25, 104, 105]. Hypercholesterolemia is generally associated with preserved EDHF responses where its enhanced activity may compensate for the decrease in NO-mediated relaxation [106–108]. Endothelium-dependent hyperpolarization appears to be inhibited in isolated gastroepiploic arteries from atherosclerotic patients, an effect that may be secondary to the duration of hypercholesterolemic injury [4]. In contrast, EDHF-mediated responses are depressed in some models of type I and type II diabetes with the exception of murine models [109].

In the healthy forearm microcirculation, we demonstrated that bradykinin-stimulated vasodilation is in part mediated by activation of K_Ca⁺ channels and that the magnitude of contribution of NO was less than the contribution of K_Ca⁺ channel activation [65]. Importantly, we found no contribution of K_Ca⁺ channel activation to acetylcholine-stimulated vasodilation in healthy subjects, either in the presence or absence of NO-blockade. Thus, acetylcholine predominantly stimulates the release of NO and no EDHF, whereas bradykinin stimulates release of both EDHF and NO. We also demonstrated a similar contribution of NO and EDHF to bradykinin-mediated vasodilation in both groups. In contrast to effects of bradykinin, forearm blood flow response to acetylcholine was diminished in hypercholesterolemic subjects when compared to healthy subjects. Moreover, in hypercholesterolemia, we observed a significant contribution of K_Ca⁺ channel activation and a lower NO release with acetylcholine that was distinctly different compared to the healthy circulation. Thus, while in health NO is the predominant contributor, in hypercholesterolemia, both NO and K_Ca⁺ channel activation contribute equally to acetylcholine-mediated microcirculatory vasodilation [65].

Evidence suggests that CYP expression [110–112] and EET generation are increased in hypertension [113, 114], during salt loading [115], and in hypercholesterolemia [116]. Members of the CYP 2C family are inhibited by NO, a phenomenon that may explain why EDHF-mediated responses are barely detectable in the absence of the combined inhibition of NO synthases and cyclooxygenase in normal vessels. Thus the EET/EDHF pathway may be of less importance in healthy vessels and of greater significance in disease states where NO activity is impaired [58]. A similar phenomenon has been described for bradykinin-induced changes in forearm blood flow in essential hypertensive patients [25] and in arterioles removed from patients with coronary artery disease, where vasodilatation is mediated entirely by a mechanism sensitive to both CYP and K_Ca⁺ channel inhibitors [9]. Such findings indicate that in the absence of NO, vascular tone can be regulated by an EDHF-like mechanism. Thus, whether EDHF plays a causal or compensatory role in the endothelial dysfunction in the human circulation remains to be elucidated.
Table 1: Pharmacological inhibitors of EDHF. Pharmacological agents used as potential inhibitors of EDHF and their targets and limitations (modified from Torondel et al. [117]).

| Pharmacological inhibitors | Targets | Comments |
|---------------------------|---------|----------|
| Apamin                    | SKCa⁺  | Highly specific |
| Charybdotoxin             | IKCa⁺ -BKCa⁺ | Can inhibit some Kv channels |
| Iberiotoxin               | BKCa⁺  | Highly specific |
| Tetraethylammonium        | SKCa⁺ -IKCa⁺ -BKCa⁺ | Inhibit other K⁺ channels at >10⁻² m |
| Tetraethybutylammonium    | SKCa⁺ -IKCa⁺ -BKCa⁺ | Inhibit other K⁺ channels at >10⁻² m |
| BaCl₂                     | KᵢR⁺   | —        |
| Ouabain                   | Na⁺/K⁺ ATPase | Can affect gap junction activity at >10⁻⁴ m |
| KCl                       | K⁺ currents | Dilates at >10⁻² m through KᵢR⁺ and Na⁺/K⁺ ATPase activation |
| 18 α-glycyrrhetic acid    | Gap junctions | Possesses nonjunctional effects on membrane currents |
| Connexin mimetic peptides | Gap junctions | Highly specific |
| Catalase                  | Hydrogen peroxide | — |
| 17-octadecenoic acid      | CYP     | Inhibits the synthesis of the vasoconstrictor 20-HETE |
| Clotrimazole              | CYP     | Can inhibit K⁺ channels |
| Miconazole                | CYP     | Can inhibit K⁺ channels |
| Sulphaphenazole           | CYP epoxygenase | Highly specific of CYP 2C9 |
| Fluconazole               | CYP epoxygenase | Can inhibit other CYP isoforms at >10⁻⁴ m |
| MSPPOH                    | EETs synthesis inhibitor | Highly specific |
| 14,15-EEZE                 | EETs antagonist | Inhibits the vasodilator action of all EETs regioisomers |

K⁺: potassium, SKCa⁺: small calcium-dependent potassium channels, IKCa⁺: intermediate calcium-dependent potassium channels, BKCa⁺: large calcium-dependent potassium channels, Kv: voltage dependent potassium channels, KᵢR⁺: inwardly rectifying potassium channels, BaCl₂: barium chloride, KCl: potassium chloride, CYP: cytochrome, 20-HETE: 20-hydroxyeicosatetraenoic acids, MSPPOH: N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide, EETs: epoxyeicosatrienoic acids, and 14,15-EEZE: 14,15-Epoxyeicosa-5(Z)-enonic Acid.

5. Summary

Absence of consensus regarding the precise identity of EDHFs and a consequent lack of specific inhibitors has long hampered clinical translation of this phenomenon (Table 1). Recently, with improved understanding of the major signaling mechanisms underlying vascular hyperpolarization, the role of EDHF in the human circulation in vivo has begun to be dissected, but experimental pitfalls remain. These include the often nonspecific nature of the antagonists used, the concentrations and duration of action of these blockers are variable, and complete blockade cannot be achieved in vivo, even with high doses, because of the competitive nature of the antagonism. Nevertheless, an impressive body of knowledge has already emerged regarding the role of EDHF in the human circulation (Table 2).

Apart from its contribution to normal vascular physiology, the accentuated role of EDHF in diseased states is worthy of further investigation because CYP-450 expression and EET generation are increased in hypertension, during salt loading and in hypercholesterolemia. Vasodilation in essential hypertension [25], and in atherosclerotic coronary arterioles, is largely secondary to CYP and KᵢR⁺ channel stimulation. There are also potential implications regarding disease susceptibility, with some polymorphisms within CYP epoxygenases being associated with an enhanced risk of developing coronary artery disease and hypertension [14]. What may ultimately be of even greater interest is development of specific agents targeting EDHF synthesis, understanding of other biological effects of EETs such as angiogenesis and modulation of cell growth, and their potential role in human disease [14].

6. Implications

Conventionally, endothelial dysfunction is characterized as a deficiency of NO activity, often secondary to exposure to cardiovascular risk factors. This leads to abnormalities in vasodilation and hence blood flow delivery. Because of the known protective role of NO on the vessel wall that impedes thrombosis and atherosclerosis, several strategies have been applied to improve NO availability/activity. Although replacing NO pharmacologically with NO donors is beneficial for symptomatic relief from coronary vasodilation, there appears to be no antiatherosclerotic effect of NO donors. Improving endothelial NO bioavailability with statins and angiotensin antagonists has nevertheless proven to be cardio-protective. What remains unknown is (a) whether enhancing EDHF in conditions with impaired NO activity would also be of therapeutic value, (b) whether agents that improve endothelial dysfunction (acetycholine responses) such as statins and angiotensin antagonists, also enhance EDHF bioactivity, and (c) whether tissue plasminogen activator release is EDHF-dependent in health and disease. Indeed hypertension is associated with elevated epoxide hydrolase expression [128, 129], angiotensin II increases the expression
Table 2: Human vascular territories with characterized EDHF activity.

| Vascular territory                  | EDHF                                           | Pharmacological agents used                                                                 |
|-------------------------------------|------------------------------------------------|-----------------------------------------------------------------------------------------------|
| **Preclinical studies**             |                                                |                                                                                               |
| Coronary arterioles [8, 9, 29, 73, 118] | \( \text{H}_2\text{O}_2, \text{K}_{\text{Ca}}^+ \text{ channels}, \text{CYP450} \text{ metabolites} \) | Catalase, KCl, charybdotoxin + Apamin, polyethylene glycol catalase, KCl, charybdotoxin, 7-octadecenoic acid, 17-octadecenoic acid, N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide4,15-eoxyeicosa-5(Z)-enoic acid |
| Internal Mammary artery [6, 62]     | 11,12-EET                                      | Catalase, 18 alpha-glycyrhrhetic acid, Tiron (cell-permeable SOD-mimetic), catalase            |
| Gastroepiploic arteries [4]         | \( \text{K}_{\text{Ca}}^+ \text{ channels} \)  | KCl, charybdotoxin, and apamin                                                                |
| Mesenteric artery [66, 119]         | \( \text{H}_2\text{O}_2, \text{Gap junctions}, \text{superoxide dismutase}, \text{H}_2\text{O}_2 \) | Ketoconazole                                                                                   |
| Renal artery [10]                   | \( \text{K}^+, \text{K}_{\text{Ca}}^+ \text{ channels} \) | Connexin mimetic peptides                                                                      |
| Subcutaneous resistance arteries [7] | \( \text{CYP450} \text{ metabolites, K}_{\text{Ca}}^+ \text{ channels} \) | Connexin 43 Gap junctions.                                                                      |
| Subcutaneous resistance arteries [120] (subcutaneous fat biopsies of healthy pregnant women) | \( \text{H}_2\text{O}_2 \) | Polyethylene glycol catalase                                                                    |
| Visceral fat arterioles [85, 121]   | \( \text{SK}_{\text{Ca}}^+ \text{ channels}, \text{IK}_{\text{Ca}}^+ \text{ channels, H}_2\text{O}_2 \) | Apamin and charybdotoxin/triaryl methane-34                                                     |
| Umbilical vein endothelial cells     | \( \text{K}_{\text{Ca}}^+ \text{ channels, K}_{\text{IR}}^+ \text{ channels, Na}^+/K^+ \text{ ATPase} \) | Iberiotoxin, charybdotoxin, apamin, glibenclamide, and barium                                 |
| Thyroid arteries [122]              | \( \text{K}_{\text{Ca}}^+ \text{ channels}, \text{K}_{\text{IR}}^+ \text{ channels, Na}^+/K^+ \text{ ATPase} \) |                                                                                               |

Clinical studies

| Forearm microvasculature [63]       | \( \text{CYP450} \text{ metabolites} \)        | KCl, miconazole                                                                               |
| Forearm microvasculature [30, 32, 123] | \( \text{K}_{\text{Ca}}^+ \text{ channels} \)  | TEA                                                                                            |
| Forearm microvasculature [124]      | \( \text{C-type natriuretic peptide} \)        | C-type natriuretic peptide, TEA                                                                |
| Forearm microvasculature [104]      | \( \text{CYP450} \text{ 2C9} \)                | Sulfaphenazole                                                                                |
| Forearm conductance vessel [31, 125, 126] | \( \text{CYP 2C9 metabolites, K}_{\text{Ca}}^+ \text{ channels} \) | Sulfaphenazole, TEA, fluconazole                                                             |
| Thigh skeletal muscle vessels [127] | \( \text{CYP450 2C9} \)                        | Sulfaphenazole                                                                                |

\( \text{H}_2\text{O}_2 \): Hydrogen Peroxide, \( \text{K}^+ \): potassium, \( \text{SK}_{\text{Ca}}^+ \): small calcium-dependent potassium channels, \( \text{IK}_{\text{Ca}}^+ \): intermediate calcium-dependent potassium channels, \( \text{K}_{\text{IR}}^+ \): inwardly rectifying potassium channels, KCl: potassium chloride, CYP: cytochrome, and EETs: epoxyeicosatrienoic acids.

of the epoxide hydrolase [130], and epoxide hydrolase inhibitors are effective in reversing the hypertensive effects of angiotensin II [128]. Thus, epoxide hydrolase inhibitors that increase epoxide levels and hence aid hyperpolarization need to be further investigated in subjects with endothelial dysfunction.

Experimental studies indicate that cytochrome P450 expression and EET generation are increased in hypertension [104, 113], in hypercholesterolemia [116], and in atherosclerotic coronary arterioles [50, 64, 75]. Moreover, polymorphisms in the cytochrome P450 epoxygenase genes are associated with increased risk of coronary artery disease and hypertension [131, 132]. Thus, understanding the pathophysiology of endothelial dysfunction beyond NO, and in particular with respect to EDHF in these disease states, could be crucial in understanding both the pathophysiology of atherosclerosis and developing novel therapies.

Acknowledgments

Professor A. Quyyumi was supported by National Institutes of Health Research Grant RO1 HL79115, and in part by PHS Grant UL1 RR025008 from the Clinical and Translational Science Award Program, and PHS Grant M01 RR00039 from the General Clinical Research Center program, National Institutes of Health, National Center for Research Resources, and the National Blood Foundation.

References

[1] A. A. Quyyumi, N. Dakak, D. Mulcahy et al., “Nitric oxide activity in the atherosclerotic human coronary circulation,” Journal of the American College of Cardiology, vol. 29, no. 2, pp. 308–317, 1997.
[2] S. Ashfaq, S. C. Beinart, J. L. Abramson et al., “Plasma glutathione redox state: a novel marker of oxidative stress,
correlates with early atherosclerosis in humans," *Journal of the American College of Cardiology*, vol. 41, pp. 293A–294A, 2003.

[3] A. A. Quyyumi, "Endothelial function in health and disease: new insights into the genesis of cardiovascular disease," *American Journal of Medicine*, vol. 105, pp. 325–395, 1998.

[4] L. Urakami-Harasawa, H. Shimokawa, M. Nakashima, K. Egashira, and A. Takeda, "Importance of endothelium-derived hyperpolarizing factor in human arteries," *Journal of Clinical Investigation*, vol. 100, no. 11, pp. 2793–2799, 1997.

[5] R. G. Woolfson and L. Poston, "Effect of NG-nitro-L-arginine on endothelium-dependent relaxation of human subcutaneous resistance arteries," *Clinical Science*, vol. 79, no. 3, pp. 273–278, 1990.

[6] S. L. Archer, F. S. Gragasin, X. Wu et al., "Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BKCa channels," *Circulation*, vol. 107, no. 5, pp. 769–776, 2003.

[7] P. Coats, F. Johnston, J. MacDonald, J. J. McMurray, and C. Hillier, "Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries," *Circulation*, vol. 103, no. 12, pp. 1702–1708, 2001.

[8] H. Miura and D. D. Gutterman, "Human coronary arterial dilatation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2+-activated K+ channels," *Circulation Research*, vol. 83, no. 5, pp. 501–507, 1998.

[9] H. Miura, R. E. Wachtel, Y. Liu et al., "Flow-induced dilation of human coronary arterioles: important role of Ca2+-activated K+ channels," *Circulation*, vol. 103, no. 15, pp. 1992–1998, 2001.

[10] E. Buusemaker, R. Popp, J. Binder, R. Busse, and I. Fleming, "Characterization of the endothelium-derived hyperpolarizing factor (EDHF) response in the human interlobar artery," *Kidney International*, vol. 63, no. 5, pp. 1749–1755, 2003.

[11] R. S. Scotland, M. Madhani, S. Chauhan et al., "Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo," *Circulation*, vol. 111, no. 6, pp. 796–803, 2005.

[12] Y. Wu, A. Huang, D. Sun, J. R. Falck, A. Koller, and G. Kaley, "Gender-specific compensation for the lack of NO in the mediation of flow-induced arteriolar dilation," *American Journal of Physiology*, vol. 280, no. 6, pp. H2456–H2461, 2001.

[13] M. Feletou and P. M. Vanhoutte, "Endothelium-derived hyperpolarizing factor: where are we now?" *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 6, pp. 1215–1225, 2006.

[14] I. Fleming and R. Busse, "Endothelium-derived epoxyeicosatrienoic acids and vascular function," *Hypertension*, vol. 47, no. 4, pp. 629–633, 2006.

[15] R. Busse, G. Edwards, M. Feletou, I. Fleming, P. M. Vanhoutte, and A. H. Weston, "EDHF: bringing the concepts together," *Trends in Pharmacological Sciences*, vol. 23, no. 8, pp. 374–380, 2002.

[16] T. B. Bolton and L. H. Clapp, "Endothelial-dependent relaxant actions of carbachol and substance P in arterial smooth muscle," *British Journal of Pharmacology*, vol. 87, no. 4, pp. 713–723, 1986.

[17] G. Chen, H. Suzuki, and A. H. Weston, "Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels," *British Journal of Pharmacology*, vol. 95, no. 4, pp. 1165–1174, 1988.

[18] R. A. Cohen and P. M. Vanhoutte, "Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP," *Circulation*, vol. 92, no. 11, pp. 3337–3349, 1995.

[19] M. Feletou and P. M. Vanhoutte, "Endothelium-dependent hyperpolarization of canine coronary smooth muscle," *British Journal of Pharmacology*, vol. 93, no. 3, pp. 515–524, 1988.

[20] A. Luckhoff, R. Zeh, and R. Busse, "Desensitization of the bradykinin-induced rise in intracellular free calcium in cultured endothelial cells," *Pflugers Archiv*, vol. 412, no. 6, pp. 654–658, 1988.

[21] R. A. Johns, N. J. Izzo, P. J. Milner, A. L. Loeb, and M. J. Peach, "Use of cultured cells to study the relationship between arachidonic acid and endothelium-derived relaxing factor," *American Journal of the Medical Sciences*, vol. 295, no. 4, pp. 287–292, 1988.

[22] G. Chen, H. Hashitani, and H. Suzuki, "Endothelium-dependent relaxation and hyperpolarization of canine coronary artery smooth muscles in relation to the electrogenic Na-K pump," *British Journal of Pharmacology*, vol. 98, no. 3, pp. 950–956, 1989.

[23] S. G. Taylor, J. S. Southerton, A. H. Weston, and J. R. Baker, "Endothelium-dependent effects of acetylcholine in rat aorta: a comparison with sodium nitroprusside and cromakalim," *British Journal of Pharmacology*, vol. 94, no. 3, pp. 853–863, 1988.

[24] M. Dawes, C. Sieniawska, T. Delves, R. Dwivedi, P. J. Chowienczyk, and J. M. Ritter, "Barium reduces resting blood flow and inhibits potassium-induced vasodilation in the human forearm," *Circulation*, vol. 105, no. 11, pp. 1323–1328, 2002.

[25] S. Taddei, L. Ghidoni, A. Virdis, S. Buralli, and A. Saltetti, "Vasodilation to bradykinin is mediated by an ouabain-sensitive pathway as a compensatory mechanism for impaired nitric oxide availability in essential hypertensive patients," *Circulation*, vol. 100, no. 13, pp. 1400–1405, 1999.

[26] C. Corriu, M. Feletou, E. Canet, and P. M. Vanhoutte, "Endothelium-derived factors and hyperpolarization of the carotid artery of the guinea-pig," *British Journal of Pharmacology*, vol. 119, no. 5, pp. 959–964, 1996.

[27] C. J. Garland and F. Plane, "Relative importance of endothelium-derived hyperpolarizing factor for the relaxation of vascular smooth muscle in different arterial beds, in *Endothelium-Derived Hyperpolarizing Factor*, P. M. Vanhoutte, Ed., pp. 173–179, Harwood Academic Publishers, 1996.

[28] P. M. Zygmunt and E. D. Hogestatt, "Role of potassium channels in endothelium-dependent relaxation resistant to nitroarginine in the rat hepatic artery," *British Journal of Pharmacology*, vol. 117, no. 7, pp. 1600–1606, 1996.

[29] H. Miura, Y. Liu, and D. D. Gutterman, "Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels," *Circulation*, vol. 99, no. 24, pp. 3122–3138, 1999.

[30] M. L. Honing, P. Smits, P. J. Morrison, and T. J. Rabelink, "Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization," *Hypertension*, vol. 35, no. 6, pp. 1314–1318, 2000.
[31] J. Bellien, R. Joannides, M. Iacob, P. Arnaud, and C. Thuillez, "Evidence for a basal release of a cytochrome P450-derived hyperpolarizing factor in the radial artery in humans," *American Journal of Physiology*, vol. 290, no. 4, pp. H1347–H1352, 2006.

[32] K. Inoue, Y. Hirooka, H. Shimokawa et al., "Role of endothelium-derived hyperpolarizing factor in human forearm circulation," *Hypertension*, vol. 42, no. 5, pp. 919–924, 2003.

[33] I. Fleming, "Cytochrome P450 and vascular homeostasis," *Circulation Research*, vol. 89, no. 9, pp. 753–762, 2001.

[34] M. Schwartzman, N. R. Ferreri, and M. A. Carroll, "Renal cytochrome P450-related arachidonate metabolite inhibits (Na⁺ + K⁺)ATPase," *Nature*, vol. 314, no. 6012, pp. 620–622, 1985.

[35] W. B. Campbell, D. Gebremedhin, P. F. Pratt, and D. R. Harder, "Identification of epoxyeicosatrienioic acids as endothelium-derived hyperpolarizing factors," *Circulation Research*, vol. 78, no. 3, pp. 415–423, 1996.

[36] M. Hecker, A. T. Bara, J. Bauersachs, and R. Busse, "Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals," *Journal of Physiology*, vol. 481, no. 2, pp. 407–414, 1994.

[37] R. Popp, J. Bauersachs, M. Hecker, I. Fleming, and R. Busse, "A transferable, beta-naphthoflavone-inducible, hyperpolarizing factor is synthesized by native and cultured porcine coronary endothelial cells," *Journal of Physiology*, vol. 497, no. 3, pp. 699–709, 1996.

[38] Y. Nishikawa, D. W. Stepp, and W. M. Chilian, "In vivo location and mechanism of EDHF-mediated vasodilation in canine coronary microcirculation," *American Journal of Physiology*, vol. 277, no. 3, pp. H1252–H1259, 1999.

[39] M. D. Widdmann, N. L. Weitnraub, J. L. Fudge, L. A. Brooks, and K. C. Dellenger, "Cytochrome P-450 pathway in acetycholine-induced canine coronary microvascular vasodilation in vivo," *American Journal of Physiology*, vol. 274, no. 1, pp. H283–H289, 1998.

[40] D. Fulton, K. Mahboubi, J. C. McGiff, and J. Quilley, "Cytochrome P450-dependent effects of bradykinin in the rat heart," *British Journal of Pharmacology*, vol. 114, no. 1, pp. 99–102, 1995.

[41] D. Fulton, J. C. McGiff, and J. Quilley, "Pharmacological evaluation of an epoxide as the putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart," *Journal of Pharmacology and Experimental Therapeutics*, vol. 287, no. 2, pp. 497–503, 1998.

[42] J. Quilley and J. C. McGiff, "Is EDHF an epoxyeicosatrienioic acid?" *Trends in Pharmacological Sciences*, vol. 21, no. 4, pp. 121–124, 2000.

[43] N. L. Weitnraub, X. Fang, T. L. Kaduce, M. Vanrollins, P. Chatterjee, and A. A. Spector, "Potentiation of endothelium-dependent relaxation by epoxyeicosatrienioic acids," *Circulation Research*, vol. 81, no. 2, pp. 258–267, 1997.

[44] Y. Nishikawa, D. W. Stepp, and W. M. Chilian, "Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo," *American Journal of Physiology*, vol. 279, no. 2, pp. H459–H465, 2000.

[45] J. Bauersachs, M. Hecker, and R. Busse, "Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation," *British Journal of Pharmacology*, vol. 113, no. 4, pp. 1548–1553, 1994.

[46] J. Alvarez, M. Montero, and J. Garcia-Sancho, "High affinity inhibition of Ca²⁺-dependent K⁺ channels by cytochrome P-450 inhibitors," *Journal of Biological Chemistry*, vol. 267, no. 17, pp. 11789–11793, 1992.

[47] D. F. Alvarez, E. A. Gjerde, and M. I. Townsley, "Role of EETs in regulation of endothelial permeability in rat lung," *American Journal of Physiology*, vol. 286, no. 2, pp. L445–L451, 2004.

[48] J. D. Imig, J. R. Falck, S. Wei, and J. H. Capdevila, "Epoxygenase metabolites contribute to nitric oxide-independent arteriolar vasodilation in response to bradykinin," *Journal of Vascular Research*, vol. 38, no. 3, pp. 247–255, 2001.

[49] B. Fisslthaler, I. Fleming, and R. Busse, "EDHF: a cytochrome P450 metabolite in coronary arteries," *Seminars in Perinatology*, vol. 24, no. 1, pp. 15–19, 2000.

[50] B. Fisslthaler, R. Popp, L. Kiss et al., "Cytochrome P450 2C is an EDHF synthase in coronary arteries," *Nature*, vol. 401, no. 6752, pp. 493–497, 1999.

[51] J. Wu, H. Dong, Z. Cai, and Y. Yu, "Stable expression of human cytochrome CYP2B6 and CYP1A1 in Chinese hamster CHL cells: their use in micronucleus assays," *Chinese Medical Sciences Journal*, vol. 12, no. 3, pp. 148–155, 1997.

[52] K. Node, Y. Huo, X. Ruan et al., "Anti-inflammatory properties of cytochrome P450 epoxyeicosanoid eicosanoids," *Science*, vol. 285, no. 5431, pp. 1276–1279, 1999.

[53] P. L. Li and W. B. Campbell, "Epoxyeicosatrienioic acids activate K⁺ channels in coronary smooth muscle through a guanine nucleotide binding protein," *Circulation Research*, vol. 80, no. 6, pp. 877–884, 1997.

[54] P. L. Li, C. L. Chen, R. Bortell, and W. B. Campbell, "11,12-epoxyeicosatrienioic acid stimulates endogenous mono-ADP-ribosylation in bovine coronary arterial smooth muscle," *Circulation Research*, vol. 85, no. 4, pp. 349–356, 1999.

[55] D. Gebremedhin, Y. H. Ma, J. R. Falck, R. J. Roman, M. Vanrollins, and D. R. Harder, "Mechanism of action of cerebral epoxyeicosatrienioic acids on cerebral arterial smooth muscle," *American Journal of Physiology*, vol. 263, no. 2, pp. H519–H525, 1992.

[56] A. Mancy, S. Dijols, S. Poli, P. Guengerich, and D. Mansuy, "Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9," *Biochemistry*, vol. 35, no. 50, pp. 16205–16212, 1996.

[57] Y. Sai, R. Dai, T. J. Yang et al., "Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450," * Xenobiotica*, vol. 30, no. 4, pp. 327–343, 2000.

[58] S. S. Bolz, S. Pieperhoff, C. De Wit, and U. Pohl, "Intact endothelial and smooth muscle function in small resistance arteries after 48 h in vessel culture," *American Journal of Physiology*, vol. 279, no. 3, pp. H1434–H1439, 2000.

[59] P. F. Prats, P. Li, C. J. Hillard, J. Kurian, and W. B. Campbell, "Endothelium-independent, ouabain-sensitive relaxation of bovine coronary arteries by EETs," *American Journal of Physiology*, vol. 280, no. 3, pp. H1113–H1121, 2001.

[60] I. Fleming, B. Fisslthaler, U. R. Michaelis, L. Kiss, R. Popp, and R. Busse, "The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells," *Pflugers Archiv*, vol. 442, no. 4, pp. 511–518, 2001.

[61] M. R. Uddin, M. M. Muthalif, N. A. Karzoun, I. F. Benter, and K. U. Malik, "Cytochrome P-450 metabolites mediate...
norepinephrine-induced mitogenic signaling,” *Hypertension*, vol. 31, no. 1, pp. 242–247, 1998.

[62] G. W. He and Z. G. Liu, “Comparison of nitric oxide release and endothelium-derived hyperpolarizing factor-mediated hyperpolarization between human radial and internal mammary arteries,” *Circulation*, vol. 104, supplement 1, pp. i344–i349, 2001.

[63] J. P. J. Halcox, S. Narayanan, L. Cramer-Joyce, R. Mineymoyer, and A. A. Quyyumi, “Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation,” *American Journal of Physiology*, vol. 280, no. 6, pp. H2470–H2477, 2001.

[64] S. Fichtlscherer, S. Dimmeler, S. Breuer, A. M. Zeheier, and I. Fleming, “Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease,” *Circulation*, vol. 109, no. 2, pp. 178–183, 2004.

[65] M. A. Ozkor, J. R. Murrow, A. M. Rahman et al., “Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease,” *Circulation*, vol. 123, no. 20, pp. 2244–2253, 2011.

[66] T. Matoba, H. Shimokawa, H. Kubota et al., “Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries,” *Biochemical and Biophysical Research Communications*, vol. 290, no. 3, pp. 909–913, 2002.

[67] R. S. Barlow and R. E. White, “Hydrogen peroxide relaxes porcine coronary arteries by stimulating BKCa channel activity,” *American Journal of Physiology*, vol. 275, no. 4, pp. H1283–H1289, 1998.

[68] R. S. Barlow, A. M. El-Mowafy, and R. E. White, “H2O2 opens BKCa channels via the PLA2-arachidonic acid signaling cascade in coronary artery smooth muscle,” *American Journal of Physiology*, vol. 279, no. 2, pp. H475–H483, 2000.

[69] J. L. Beny and P. Y. von der Weid, “Hydrogen peroxide: an endogenous smooth muscle cell hyperpolarizing factor,” *Biochemical and Biophysical Research Communications*, vol. 176, no. 1, pp. 378–384, 1991.

[70] G. M. Rubanyi, J. C. Romero, and P. M. Vanhoutte, “Flow-induced release of endothelium-derived relaxing factor,” *American Journal of Physiology*, vol. 250, no. 6, pp. H1145–H1149, 1986.

[71] T. Matoba, H. Shimokawa, M. Nakashima et al., “Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice,” *Journal of Clinical Investigation*, vol. 106, no. 12, pp. 1521–1530, 2000.

[72] Z. Lacza, M. Puskar, B. Kis, J. V. Perciaccante, A. W. Miller, and D. W. Bussja, “Hydrogen peroxide acts as an EDHF in the piglet pial vasculature in response to bradykinin,” *American Journal of Physiology*, vol. 283, no. 1, pp. H406–H411, 2002.

[73] H. Miura, J. J. Bosnjak, G. Ning, T. Saito, M. Miura, and D. D. Gutterman, “Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles,” *Circulation Research*, vol. 92, no. 2, pp. e31–e40, 2003.

[74] T. Yada, H. Shimokawa, O. Hiramatsu et al., “Hydrogen peroxide, an endogenous endothelium-derived hyperpolarizing factor, plays an important role in coronary autoregulation in vivo,” *Circulation*, vol. 107, no. 7, pp. 1040–1045, 2003.

[75] I. Fleming, U. R. Michaelis, D. Bredenkötter et al., “Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries,” *Circulation Research*, vol. 88, no. 1, pp. 44–51, 2001.

[76] Z. S. Katusic, “Superoxide anion and endothelial regulation of arterial tone,” *Free Radical Biology & Medicine*, vol. 20, no. 3, pp. 443–448, 1996.

[77] U. Bayraktutan, L. Blayney, and A. M. Shah, “Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 8, pp. 1903–1911, 2000.

[78] A. Sato, I. Sakuma, and D. D. Gutterman, “Mechanism of dilation to reactive oxygen species in human coronary arterioles,” *American Journal of Physiology*, vol. 285, no. 6, pp. H2345–H2354, 2003.

[79] Y. Liu, H. Zhao, H. Li, B. Kalyanaraman, A. C. Nicolosi, and D. D. Gutterman, “Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries,” *Circulation Research*, vol. 93, no. 6, pp. 573–580, 2003.

[80] C. A. Hamilton, A. R. Mcphaden, G. Berg, V. Pathi, and A. F. Dominiczak, “Is hydrogen peroxide an EDHF in human radial arteries?” *American Journal of Physiology*, vol. 280, no. 6, pp. H2451–H2455, 2001.

[81] C. A. Hamilton, R. Williams, V. Pathi et al., “Pharmacological characterisation of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery,” *Cardiovascular Research*, vol. 42, no. 1, pp. 214–223, 1999.

[82] Y. Hayabuchi, Y. Nakaya, S. Matsuoka, and Y. Kuroda, “Hydrogen peroxide-induced vascular relaxation in porcine coronary arteries is mediated by Ca2+-activated K+ channels,” *Heart and Vessels*, vol. 13, no. 1, pp. 9–17, 1998.

[83] C. G. Sobey, D. D. Heistad, and F. M. Faraci, “Mechanisms of bradykinin-induced cerebral vasodilation in rats: evidence that reactive oxygen species activate K+ channels,” *Stroke*, vol. 28, no. 11, pp. 2290–2294, 1997.

[84] E. P. Wei, H. A. Kontos, and J. S. Beckman, “Mechanisms of cerebral vasodilation by superoxide, hydrogen peroxide, and peroxynitrite,” *American Journal of Physiology*, vol. 271, no. 3, pp. H1262–H1266, 1996.

[85] R. Bychkov, K. Pieper, C. Ried et al., “Hydrogen peroxide, potassium currents, and membrane potential in human endothelial cells,” *Circulation*, vol. 99, no. 13, pp. 1719–1725, 1999.

[86] A. Mugge, J. A. Lopez, D. J. Piegors, K. R. Breese, and D. D. Heistad, “Acetylcholine-induced vasodilation in rabbit hindlimb in vivo is not inhibited by analogues of L-arginine,” *American Journal of Physiology*, vol. 260, no. 1, pp. H242–H247, 1991.

[87] J. Bauersachs, R. Popp, M. Hecker, E. Sauer, I. Fleming, and R. Busse, “Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor,” *Circulation*, vol. 94, no. 12, pp. 3341–3347, 1996.

[88] L. Olmos, J. V. Mombouli, S. Illiano, and P. M. Vanhoutte, “cGMP mediates the desensitization to bradykinin in isolated canine coronary arteries,” *The American Journal of Physiology*, vol. 268, no. 2, pp. H865–H870, 1995.

[89] J. V. Mombouli and P. M. Vanhoutte, “Endothelium-derived hyperpolarizing factor(s): updating the unknown,” *Trends in Pharmacological Sciences*, vol. 18, no. 7, pp. 252–256, 1997.

[90] D. M. Gilligan, J. A. Panza, C. M. Kilcoyne, M. A. Waclawiw, P. R. Casino, and A. A. Quyyumi, “Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation,” *Circulation*, vol. 90, no. 6, pp. 2853–2858, 1994.

[91] R. Joannides, W. E. Haefeli, L. Linder et al., “Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo,” *Circulation*, vol. 91, no. 5, pp. 1314–1319, 1995.
[123] P. Pickkers, A. D. Hughes, E. G. Russel, T. Thien, and P. Smits, “Thiazide-induced vasodilation in humans is mediated by potassium channel activation,” Hypertension, vol. 32, no. 6, pp. 1071–1076, 1998.

[124] M. L. Honing, P. Smits, P. J. Morrison, J. C. Burnett Jr., and T. J. Rabelink, “C-type natriuretic peptide-induced vasodilation is dependent on hyperpolarization in human forearm resistance vessels,” Hypertension, vol. 37, no. 4, pp. 1179–1183, 2001.

[125] D. Fischer, U. Landmesser, S. Spiekermann et al., “Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in patients with chronic heart failure,” European Journal of Heart Failure, vol. 9, no. 8, pp. 770–775, 2007.

[126] J. Bellien, R. Joannides, M. Iacob, P. Arnaud, and C. Thuillez, “Calcium-activated potassium channels and NO regulate human peripheral conduit artery mechanics,” Hypertension, vol. 46, no. 1, pp. 210–216, 2005.

[127] T. Hillig, P. Krstrup, I. Fleming, T. Osada, B. Saltin, and Y. Hellsten, “Cytochrome P450 2C9 plays an important role in the regulation of exercise-induced skeletal muscle blood flow and oxygen uptake in humans,” Journal of Physiology, vol. 546, no. 1, pp. 307–314, 2003.

[128] J. D. Imig, “Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases,” American Journal of Physiology, vol. 289, no. 3, pp. F496–F503, 2005.

[129] Z. Yu, F. Xu, L. M. Huse et al., “Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids,” Circulation Research, vol. 87, no. 11, pp. 992–998, 2000.

[130] D. Ai, Y. Fu, D. Guo et al., “Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 9018–9023, 2007.

[131] M. Spiecker, H. Darius, T. Hankeln et al., “Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2,” Circulation, vol. 110, no. 15, pp. 2132–2136, 2004.

[132] B. N. Yu, C. H. Luo, D. Wang et al., “CYP2C9 allele variants in Chinese hypertension patients and healthy controls,” Clinica Chimica Acta, vol. 348, no. 1-2, pp. 57–61, 2004.
Submit your manuscripts at http://www.hindawi.com